The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
A Current Perspective on Daptomycin for the Clinical Microbiologist
Open accessAbstract
SUMMARY: Daptomycin is a lipopeptide antimicrobial with in vitro bactericidal activity against Gram-positive bacteria that was first approved for clinical use in 2004 in the United States. Since this time, significant data have emerged regarding the use of daptomycin for the treatment of serious infections, such as bacteremia and endocarditis, caused by Gram-positive pathogens. However, there are also increasing reports of daptomycin nonsusceptibility, in Staphylococcus aureus and, in particular, Enterococcus faecium and Enterococcus faecalis . Such nonsusceptibility is largely in the context of prolonged treatment courses and infections with high bacterial burdens, but it may occur in the absence of prior daptomycin exposure. Nonsusceptibility in both S. aureus and Enterococcus is mediated by adaptations to cell wall homeostasis and membrane phospholipid metabolism. This review summarizes the data on daptomycin, including daptomycin's unique mode of action and spectrum of activity and mechanisms for nonsusceptibility in key pathogens, including S. aureus , E. faecium , and E. faecalis . The challenges faced by the clinical laboratory in obtaining accurate susceptibility results and reporting daptomycin MICs are also discussed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Antibiotic resistance is prevalent in an isolated cave microbiome
Bhullar, K., Waglechner, N., Pawlowski, A., Koteva, K., Banks, E. D., Johnston, M. D., Barton, H. A., & Wright, G. D. (2012) · PLoS ONE · doi:10.1371/journal.pone.0034953 · Cited by 736
Inhibition of Daptomycin by Pulmonary Surfactant: In Vitro Modeling and Clinical Impact
Silverman, J. A., Mortin, L. I., VanPraagh, A. D. G., Li, T., & Alder, J. (2005) · The Journal of Infectious Diseases · doi:10.1086/430352 · Cited by 541 · cited 6×
“In contrast, ceftriaxone reduces the bacterial burden in this setting by greater than 5 orders of magnitude (50).”
BackgroundInfluentialA Cholesterol Biosynthesis Inhibitor Blocks Staphylococcus aureus Virulence
Liu, C.-I., Liu, G. Y., Song, Y., Yin, F., Hensler, M. E., Jeng, W.-Y., Nizet, V., Wang, A. H.-J., & Oldfield, E. (2008) · Science · doi:10.1126/science.1153018 · Cited by 490
Genetic Basis for In Vivo Daptomycin Resistance in Enterococci
Arias, C. A., Panesso, D., McGrath, D. M., Qin, X., Mojica, M. F., Miller, C., Diaz, L., Tran, T. T., Rincon, S., Barbu, E. M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1011138 · Cited by 377
Pogliano, J., Pogliano, N., & Silverman, J. A. (2012) · Journal of Bacteriology · doi:10.1128/jb.00011-12 · Cited by 319
Bayer, A. S., Schneider, T., & Sahl, H. (2013) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2012.06819.x · Cited by 311
Dhand, A., Bayer, A. S., Pogliano, J., Yang, S.-J., Bolaris, M., Nizet, V., Wang, G., & Sakoulas, G. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/cir340 · Cited by 252
Self-citationSakoulas, G., Bayer, A. S., Pogliano, J., Tsuji, B. T., Yang, S.-J., Mishra, N. N., Nizet, V., Yeaman, M. R., & Moise, P. A. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.05551-11 · Cited by 176
Self-citationWerth, B. J., Sakoulas, G., Rose, W. E., Pogliano, J., Tewhey, R., & Rybak, M. J. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01586-12 · Cited by 134
Self-citationTran, T. T., Panesso, D., Gao, H., Roh, J. H., Munita, J. M., Reyes, J., Diaz, L., Lobos, E. A., Shamoo, Y., Mishra, N. N., et al. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01454-12 · Cited by 125
Munita, J. M., Panesso, D., Diaz, L., Tran, T. T., Reyes, J., Wanger, A., Murray, B. E., & Arias, C. A. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00509-12 · Cited by 118 · cited 2×
“Mutations associated with daptomycin nonsusceptibility (such as liaFSR) in daptomycinsusceptible enterococci (78) and inferior daptomycin treatment outcomes in E.”
BackgroundRose, W. E., Leonard, S. N., Sakoulas, G., Kaatz, G. W., Zervos, M. J., Sheth, A., Carpenter, C. F., & Rybak, M. J. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00869-07 · Cited by 81
Self-citationMunita, J. M., Tran, T. T., Diaz, L., Panesso, D., Reyes, J., Murray, B. E., & Arias, C. A. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00021-13 · Cited by 70 · cited 1×
“faecalis isolate with a daptomycin-susceptible MIC of 4 g/ml but a mutated liaF allele introduced via allelic exchange was daptomycin tolerant in vitro (80).”
BackgroundSakoulas, G., Nonejuie, P., Nizet, V., Pogliano, J., Crum-Cianflone, N., & Haddad, F. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02481-12 · Cited by 65
Self-citationSchutt, A. C., & Bohm, N. M. (2009) · Annals of Pharmacotherapy · doi:10.1345/aph.1m324 · Cited by 57
Chambers, H. F., Basuino, L., Diep, B. A., Steenbergen, J., Zhang, S., Tattevin, P., & Alder, J. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01307-08 · Cited by 42
Cited by
Global Emergence and Dissemination of Enterococci as Nosocomial Pathogens: Attack of the Clones?
Guzman Prieto, A. M., van Schaik, W., Rogers, M. R. C., Coque, T. M., Baquero, F., Corander, J., & Willems, R. J. L. (2016) · Frontiers in Microbiology · doi:10.3389/fmicb.2016.00788 · Cited by 385
An overview of antimicrobial peptides and the latest advances in their development
Sierra, J. M., Fusté, E., Rabanal, F., Vinuesa, T., & Viñas, M. (2017) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2017.1315402 · Cited by 283
Bender, J. K., Cattoir, V., Hegstad, K., Sadowy, E., Coque, T. M., Westh, H., Hammerum, A. M., Schaffer, K., Burns, K., Murchan, S., et al. (2018) · Drug Resistance Updates · doi:10.1016/j.drup.2018.10.002 · Cited by 281
Advances in Development of Antimicrobial Peptidomimetics as Potential Drugs
Molchanova, N., Hansen, P., & Franzyk, H. (2017) · Molecules · doi:10.3390/molecules22091430 · Cited by 257
Metadata
- Authors
- Humphries, R. M., Pollett, S., & Sakoulas, G.
- Venue
- Clinical Microbiology Reviews
- Publisher
- American Society for Microbiology
- Published
- 2013-10
- Volume
- 26
- Issue
- 4
- Pages
- 759-780
- ISSN
- 0893-8512 (ISSN-L)
- 1098-6618
- OpenAlex
- W2108797565
- Cited by
- 240
- References
- 16
- FWCI
- 13.91
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.